Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. (Q53837214)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. (English)

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

2

object named as

Toshihiko Doi

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Charles S. Fuchs

1

object named as

Charles S Fuchs

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Shadia I. Jalal

8

object named as

Shadia I Jalal

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

24

object named as

Yung-Jue Bang

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

16

object named as

Atsushi Ohtsu

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

author name string

Raymond W Jang

3

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Kei Muro

4

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Taroh Satoh

5

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Manuela Machado

6

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Weijing Sun

7

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Manish A Shah

9

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Jean-Phillipe Metges

10

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Marcelo Garrido

11

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Talia Golan

12

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Mario Mandala

13

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Zev A Wainberg

14

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Daniel V Catenacci

15

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Kohei Shitara

17

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Ravit Geva

18

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Jonathan Bleeker

19

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Andrew H Ko

20

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Geoffrey Ku

21

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Philip Philip

22

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Peter C Enzinger

23

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Diane Levitan

25

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Jiangdian Wang

26

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Minori Rosales

27

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Rita P Dalal

28

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Harry H Yoon

29

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

publication date

15 March 2018

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: A systematic review and meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

New agents on the horizon in gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

Global cancer statistics, 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

Comprehensive molecular characterization of gastric adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

Chemotherapy for advanced gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

22 May 2018

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

13 August 2018

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

13 August 2018

Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

13 August 2018

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5885175

13 August 2018

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

1 reference

https://pubmed.ncbi.nlm.nih.gov/29543932

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1001/JAMAONCOL.2018.0013

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

1 reference

Europe PubMed Central

20 May 2018

http://europepmc.org/abstract/PMC/5885175

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53837214&oldid=1777449915"